Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection

Vaccine

Volumn 27, Issue 14, 2009, Pages 2070-2076

  Gao, Xiang ^a   Cai, Kun ^a   Shi, Jing ^a   Liu, Hao ^a   Hou, Xiaojun ^a   Tu, Wei ^a   Xiao, Le ^a   Wang, Qin ^a   Wang, Hui ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

EHEC; Fusion protein; Immunogenicity; Shiga toxin B subunit

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G1; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN STX1B; RECOMBINANT PROTEIN STX2B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TH2 CELL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIOLYSIS; ESCHERICHIA COLI O157; FEMALE; HEMOLYTIC-UREMIC SYNDROME; IMMUNE SERA; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SHIGA TOXIN 1; SHIGA TOXIN 2; TH2 CELLS;

EID: 61849179644     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.115     Document Type: Article

References (23)

1. Karmali M.A. Laboratory diagnosis of verotoxin-producing Escherichia coli infections. Clin Microbiol Newsl 9 9 (1987) 65-69
2. Karmali M.A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 2 1 (1989) 15-38
3. Boerlin P., McEwen S.A., Boerlin-Petzold F., Wilson J.B., Johnson R.P., and Gyles C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 37 3 (1999) 497-503
4. Kleanthous H., Smith H.R., Scotland S.M., Gross R.J., Rowe B., Taylor C.M., et al. Haemolytic uraemic syndromes in the British Isles, 1985-1998: association with Verocytotoxin producing Escherichia coli. Part 2. Microbiological aspects. Arch Dis Child 65 7 (1990) 722-727
5. Ostroff S.M., Tarr P.I., Neill M.A., Lewis J.H., Hargrett-Bean N., and Kobayashi J.M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160 6 (1989) 994-998
6. Marcato P., Griener T.P., Mulvey G.L., and Armstrong G.D. Recombinant shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from shigatoxemia. Infect Immun 73 10 (2005) 6523-6529
7. Acheson D.W., De Breucker S.A., Jacewicz M., Lincicome L.L., Donohue-Rulfe A., Kane A.V., et al. Expression and purification of shiga-like toxin II B subunits. Infect Immun 63 1 (1995) 301-308
8. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., and Keusch G.T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163 6 (1986) 1391-1404
9. Lingwood C.A. Role of verotoxin receptors in pathogenesis. Trends Microbiol 4 4 (1996) 147-153
10. Stein P.E., Boodhoo A., Tyrrell G.J., Brunton J.L., and Read R.J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 355 6362 (1992) 748-750
11. Donohue-Rolfe A., Acheson D.W., Kane A.V., and Keusch G.T. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun 57 12 (1989) 3888-3893
12. Boyd B., Richardson S., and Gariepy J. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin. Infect Immun 59 3 (1991) 750-757
13. Acheson D.W.K., Levine M.M., Kaper J.B., and Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 64 1 (1996) 355-357
14. Butterton J.R., Ryan E.T., Acheson D.W., and Calderwood S.B. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun 65 (1997) 2127-2135
15. Wen S.X., Teel L.D., Judge N.A., and O'Brien A.D. Genetic toxiods of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24 8 (2006) 1142-1148
16. Smith M.J., Teel L.D., Carvalho H.M., Melton-Celsa A.R., and O'Brien A.D. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxin types 1 and 2. Vaccine 24 19 (2006) 4122-4129
17. Bielaszewska M., Clarke I., Karmali M.A., and Petric M. Localization of intravenously administered Verocytotoxins (Shiga-Like Toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun 65 7 (1997) 2509-2516
18. Paton J.C., and Paton A.W. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 11 7 (1998) 450-479
19. Marcato P., Mulvey G., Read R.J., Helm K.V., Nation P.N., and Armstrong G.D. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 183 3 (2001) 435-443
20. Acheson D.W., Levine M.M., Kaper J.B., and Keusch G.T. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 64 1 (1996) 355-357
21. Lim Y.S., Kang B.Y., Kim E.J., Kim S.H., Hwang S.Y., and Kim T.S. Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct. Immunology 94 2 (1998) 135-141
22. Capozzo A.V., Pistone Creydt V., Dran G., Fernández G., Gómez S., Bentancor L.V., et al. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun 71 7 (2003) 3971-3978
23. Ohmura M., Yamamoto M., Tomiyama-Miyaji C., Yuki Y., Takeda Y., and Kiyono H. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect Immun 73 7 (2005) 4088-4097